Literature DB >> 15692838

Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.

Ulrike Bacher1, Torsten Haferlach, Wolfgang Kern, Wolfgang Hiddemann, Susanne Schnittger, Claudia Schoch.   

Abstract

In chronic myeloproliferative disorders other than CML (CMPD) recurrent cytogenetic abnormalities occur, but specific patterns of chromosomal aberrations in the specific entities have so far not been detected. Thus, the value of conventional cytogenetics in the routine diagnostic setting of CMPD remains to be clarified. We performed a cytogenetic study on 409 patients with different CMPD [polycythemia vera, essential thrombocytosis (ET), idiopathic osteomyelofibrosis, chronic myelomonocytic leukemia (proliferative subtype), idiopathic hypereosinophilic syndrome (HES), myeloproliferative syndrome (unclassifiable)] and on 102 patients with suspected CMPD. Cytogenetic abnormalities occurred in different frequencies ranging from 3 to 40% depending on the subtype, and showed some specific differences with respect to their type. The highest frequency and the most complex pattern of clonal aberrations were observed in idiopathic osteomyelofibrosis. However, clonal aberrations were also found in 10% of patients with suspected CMPD establishing the diagnosis of a malignant disease. In conclusion, cytogenetics are essential in the routine diagnostic setting of CMPD or cases suspicious for CMPD. In ET and in HES the aberration rate was only 3 and 7%, respectively. Thus, cytogenetics can be omitted. However, in some of these cases molecular procedures should be integrated into the routine diagnostic process.

Entities:  

Mesh:

Year:  2005        PMID: 15692838     DOI: 10.1007/s00277-004-0977-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  12 in total

1.  Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.

Authors:  Manja Meggendorfer; Torsten Haferlach; Tamara Alpermann; Sabine Jeromin; Claudia Haferlach; Wolfgang Kern; Susanne Schnittger
Journal:  Haematologica       Date:  2014-09-19       Impact factor: 9.941

Review 2.  Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups.

Authors:  Francesco Onida; Giovanni Barosi; Giuseppe Leone; Luca Malcovati; Enrica Morra; Valeria Santini; Giorgina Specchia; Sante Tura
Journal:  Haematologica       Date:  2013-09       Impact factor: 9.941

3.  Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.

Authors:  Guilin Tang; Liping Zhang; Bin Fu; Jianhua Hu; Xinyan Lu; Shimin Hu; Ankita Patel; Maitrayee Goswami; Joseph D Khoury; Guillermo Garcia-Manero; L Jeffrey Medeiros; Sa A Wang
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

Review 4.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

5.  Significance of cytogenetic abnormalities in patients with polycythemia vera.

Authors:  Matjaz Sever; Alfonso Quintás-Cardama; Sherry Pierce; Lingsha Zhou; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-04-17

6.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Authors:  Gerlinde Wernig; Thomas Mercher; Rachel Okabe; Ross L Levine; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

7.  Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.

Authors:  Piyanuch Kongtim; Uday Popat; Antonio Jimenez; Sameh Gaballa; Riad El Fakih; Gabriela Rondon; Julianne Chen; Carlos Bueso-Ramos; Gautam Borthakur; Naveen Pemmaraju; Guillermo Garcia-Manero; Hagop Kantarjian; Amin Alousi; Chitra Hosing; Paolo Anderlini; Issa F Khouri; Partow Kebriaei; Borje S Andersson; Betul Oran; Katayoun Rezvani; David Marin; Elizabeth J Shpall; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-04       Impact factor: 5.742

Review 8.  Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.

Authors:  Nisha R Singh
Journal:  Transl Pediatr       Date:  2015-04

9.  Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.

Authors:  Matjaz Sever; Hagop Kantarjian; Sherry Pierce; Nitin Jain; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

Review 10.  The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Authors:  Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.